Valbenazine Significantly Decreases Tardive Dyskinesia in Patients With Schizophrenia
TAMPA, Fla -- April 10, 2017 -- Valbenazine, administered once daily, can significantly reduce tardive dyskinesia in patients with schizophrenia, schizoaffective disorder, and mood disorder, according to a study published in the American Journal of Psychiatry.
“One approach to managing tardive dyskinesia is to discontinue antipsychotic treatment or reduce the dosage, but these options are not always feasible, because withdrawal can exacerbate tardive dyskinesia symptoms or have a negative impact on psychiatric status,” said Robert A. Hauser, MD, University of South Florida, Tampa, Florida. “Moreover, tardive dyskinesia symptoms often persist even after discontinuation or dosage reduction.”
In a 6-week double-blind study, 225 patients with schizophrenia, schizoaffective disorder or a mood disorder who had moderate or severe tardive dyskinesia were randomised in a 1:1:1 ratio to receive once-daily placebo, valbenazine 40 mg/day or valbenazine 80 mg/day.
The primary endpoint was change from baseline to week 6 on the Abnormal Involuntary Movement Scale (AIMS) dyskinesia score (items 1-7), as assessed by blinded central AIMS video raters.
A total of 205 patients completed the study. Least squares mean change from baseline to week 6 in AIMS dyskinesia score was -3.2 for the 80 mg group, compared with -0.1 for the placebo group.
AIMS dyskinesia score was only reduced by -1.9 in the valbenazine 40 mg/day group.
The incidence of adverse events was consistent with previous studies. Drowsiness, restlessness and dry mouth were reported as adverse effects.
“Once-daily valbenazine significantly improved tardive dyskinesia in patients with underlying schizophrenia, schizoaffective disorder, or mood disorder,” the authors wrote. “Valbenazine was generally well tolerated, and psychiatric status remained stable.”
The researchers noted that longer trials are necessary to understand the long-term effects of valbenazine in patients with tardive dyskinesia.
SOURCE: University of South Florida
DG News lets you be the first to know advances in medical research, results from conferences, and changes in healthcare policy and business.